Overexpression of STAT3 and its main regulator IL6 is reported in the literature but IL6 inhibitory effect in prostate cancer progression and failure of STAT3-IL6 axis targeting as potential therapeutic target in patients were reported as well. Here, IL6 is linked to prostate cancer.